Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery ...

Key players in the sinusitis drug pipeline market include Bayer, Sanofi, and Pfizer, among others. These companies are at the forefront of developing cutting-edge therapies to improve patient ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Key players in the sinusitis drug pipeline market include Bayer, Sanofi, and Pfizer, among others. These companies are at the forefront of developing cutting-edge therapies to improve patient outcomes ...

Enveda, a Colorado-based biotech, has received a $20 million investment from French pharma major Sanofi (Euronext ... Enveda has made significant progress in building a deep pipeline of molecules with ...

While early-stage, the Adagene deal is another example of Sanofi's determination to bolster its R&D pipeline via a string of deals, including a $5.2 billion, strategic-level alliance with UK ...

The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.A recent comprehensive analysis of the Chronic ...

Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials: Boulder, Colorado Friday, February 28, 2025, 16:00 Hrs [IST] Enveda, a leading biotechnolog ...